ARTICLE | Clinical News
Cladribine tablets: Completed Phase III enrollment
November 22, 2010 8:00 AM UTC
Merck's Merck Serono S.A. unit completed enrollment of 617 patients at risk of developing MS in the double-blind, placebo-controlled, international Phase III ORACLE MS trial evaluating 2 dose regimen...